$ARTH
Arch Therapeutics, Inc. Stock $arth

$arth Overview Financials Valuation SEC Filings Company Website

2016 Q3 Form 10-K Financial Statement

#000114420416137852 Filed on December 05, 2016

Income Statement

Concept	2016 Q3	2016	2015 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.340M	$4.367M	$1.160M
YoY Change	15.52%	18.02%	34.88%
% of Gross Profit
Research & Development	$440.0K	$1.683M	$430.0K
YoY Change	2.33%	-4.36%	-18.87%
% of Gross Profit
Depreciation & Amortization		$0.00	$0.00
YoY Change
% of Gross Profit
Operating Expenses	$1.780M	$6.051M	$1.600M
YoY Change	11.25%	10.81%	15.11%
Operating Profit		-$6.051M
YoY Change		10.81%
Interest Expense	-$30.00K	$276.7K	$410.0K
YoY Change	-107.32%	-26.76%	-79.7%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$1.820M	-$5.992M	-$1.100M
YoY Change	65.45%	103.3%	-271.88%
Income Tax
% Of Pretax Income
Net Earnings	-$1.820M	-$5.992M	-$1.100M
YoY Change	65.45%	103.3%	-271.88%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$12.40K	-$49.33K	-$11.07K
COMMON SHARES
Basic Shares Outstanding	134.2M shares		100.6M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q3	2016	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.040M	$5.036M	$3.960M
YoY Change	27.27%	27.18%	377.11%
Cash & Equivalents	$5.036M		$3.960M
Short-Term Investments
Other Short-Term Assets	$110.0K	$107.8K	$40.00K
YoY Change	175.0%	151.12%	0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$5.144M	$5.144M	$4.003M
YoY Change	28.51%	28.51%	356.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$0.00		$0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00
YoY Change
Total Long-Term Assets	$0.00	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$5.144M	$5.144M	$4.003M
Total Long-Term Assets	$0.00	$0.00	$0.00
Total Assets	$5.144M	$5.144M	$4.003M
YoY Change	28.51%	28.51%	356.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$374.9K	$374.9K	$231.8K
YoY Change	61.76%	61.76%	31.81%
Accrued Expenses	$600.0K	$604.3K	$250.0K
YoY Change	140.0%	146.15%	-7.41%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$900.0K	$899.6K	$470.0K
YoY Change	91.49%	89.9%
Total Short-Term Liabilities	$1.879M	$1.879M	$1.286M
YoY Change	46.09%	46.09%	-52.78%
LONG-TERM LIABILITIES
Long-Term Debt	$80.00K	$78.26K	$970.0K
YoY Change	-91.75%	-91.91%	1.04%
Other Long-Term Liabilities	$30.00K	$26.23K	$210.0K
YoY Change	-85.71%	-87.51%	-94.87%
Total Long-Term Liabilities	$104.5K	$104.5K	$1.177M
YoY Change	-91.12%	-91.12%	-76.68%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.879M	$1.879M	$1.286M
Total Long-Term Liabilities	$104.5K	$104.5K	$1.177M
Total Liabilities	$1.983M	$1.983M	$2.463M
YoY Change	-19.47%	-19.47%	-68.3%
SHAREHOLDERS EQUITY
Retained Earnings	-$21.71M		-$15.72M
YoY Change	38.11%		23.07%
Common Stock	$24.88M		$17.26M
YoY Change	44.1%		193.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.161M	$3.161M	$1.540M
YoY Change
Total Liabilities & Shareholders Equity	$5.144M	$5.144M	$4.003M
YoY Change	28.51%	28.51%	356.45%

Cashflow Statement

Concept	2016 Q3	2016	2015 Q3
OPERATING ACTIVITIES
Net Income	-$1.820M	-$5.992M	-$1.100M
YoY Change	65.45%	103.3%	-271.88%
Depreciation, Depletion And Amortization		$0.00	$0.00
YoY Change
Cash From Operating Activities	-$1.090M	-$4.747M	-$1.610M
YoY Change	-32.3%	11.97%	65.98%
INVESTING ACTIVITIES
Capital Expenditures		$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$100.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	370.0K	$5.823M	2.300M
YoY Change	-83.91%	-20.94%
NET CHANGE
Cash From Operating Activities	-1.090M	-$4.747M	-1.610M
Cash From Investing Activities		$0.00
Cash From Financing Activities	370.0K	$5.823M	2.300M
Net Change In Cash	-720.0K	$1.076M	690.0K
YoY Change	-204.35%	-65.57%	-171.13%
FREE CASH FLOW
Cash From Operating Activities	-$1.090M	-$4.747M	-$1.610M
Capital Expenditures		$0.00
Free Cash Flow		-$4.747M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-5460514	USD
CY2016	dei	Entity Registrant Name EntityRegistrantName	Arch Therapeutics, Inc.
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	137882075	shares
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-2947526	USD
CY2016	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedAggregateIntrinsicValue	0	USD
CY2016	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodAggregateIntrinsicValue	0	USD
CY2016Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets	3925	USD
CY2015Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3925	USD
CY2015Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets	3925	USD
CY2016Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	458417	USD
CY2015Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1014654	USD
CY2016Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	8624010	USD
CY2016Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8624010	USD
CY2016Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2015Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	9509000	USD
CY2015Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	8487000	USD
CY2015	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2130000	USD
CY2016	dei	Entity Central Index Key EntityCentralIndexKey	0001537561
CY2016	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2016	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2016	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2016	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2016	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2016Q1	dei	Entity Public Float EntityPublicFloat	27300000	USD
CY2016	dei	Trading Symbol TradingSymbol	ARTH
CY2016Q3	us-gaap	Accounts Payable And Accrued Liabilities Noncurrent AccountsPayableAndAccruedLiabilitiesNoncurrent	26230	USD
CY2015Q3	us-gaap	Accounts Payable And Accrued Liabilities Noncurrent AccountsPayableAndAccruedLiabilitiesNoncurrent	210000	USD
CY2016Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	104485	USD
CY2015Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1176824	USD
CY2016Q3	us-gaap	Liabilities Liabilities	1983265	USD
CY2015Q3	us-gaap	Liabilities Liabilities	2462902	USD
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	134432	USD
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	107392	USD
CY2016Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	24741153	USD
CY2015Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	17154945	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-21714590	USD
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15722220	USD
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	3160995	USD
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	1540117	USD
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5144260	USD
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4003019	USD
CY2016Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	USD
CY2015Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	473747	USD
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1286078	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1878780	USD
CY2015Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	335092	USD
CY2016Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2015Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	245478	USD
CY2016Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	299487	USD
CY2015Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	231761	USD
CY2016Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	374896	USD
CY2015Q3	us-gaap	Assets Assets	4003019	USD
CY2016Q3	us-gaap	Assets Assets	5144260	USD
CY2015Q3	us-gaap	Assets Current AssetsCurrent	4003019	USD
CY2016Q3	us-gaap	Assets Current AssetsCurrent	5144260	USD
CY2015Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	42919	USD
CY2016Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	107784	USD
CY2015Q3	us-gaap	Cash Cash	3960100	USD
CY2016Q3	us-gaap	Cash Cash	5036476	USD
CY2015	us-gaap	Revenues Revenues	0	USD
CY2016	us-gaap	Revenues Revenues	0	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3700477	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4367476	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1760037	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1683299	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	5460514	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	6050775	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-6050775	USD
CY2015	us-gaap	Interest Expense InterestExpense	377805	USD
CY2016	us-gaap	Interest Expense InterestExpense	276687	USD
CY2016	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	58405	USD
CY2015	arth	Gain On Exercise Of Warrants GainOnExerciseOfWarrants	386612	USD
CY2016	arth	Gain On Exercise Of Warrants GainOnExerciseOfWarrants	142964	USD
CY2015	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-1032113	USD
CY2016	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2015	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	3536294	USD
CY2016	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	192128	USD
CY2015	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	2512988	USD
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M24D
CY2016	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm	P6Y3M4D
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-5992370	USD
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	121462897	shares
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	81394873	shares
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	1047685	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	1098160	USD
CY2015	arth	Noncash Interest Expense On Notes Payable NoncashInterestExpenseOnNotesPayable	377805	USD
CY2016	arth	Noncash Interest Expense On Notes Payable NoncashInterestExpenseOnNotesPayable	276687	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-551	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	64865	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	55929	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	137420	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-49194	USD
CY2016	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	80533	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4239386	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4747027	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	7365966	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5823403	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3126580	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1076376	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	833520	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3960100	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5036476	USD
CY2015	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3600000	USD
CY2016	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2708749	USD
CY2015	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-3536294	USD
CY2016	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-192128	USD
CY2015	arth	Change To Gain Or Loss On Warrant Modification ChangeToGainOrLossOnWarrantModification	-1032113	USD
CY2016	arth	Change To Gain Or Loss On Warrant Modification ChangeToGainOrLossOnWarrantModification	0	USD
CY2016	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	644900	USD
CY2015	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	151173	USD
CY2016	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-52500	USD
CY2015	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-166157	USD
CY2016	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2015	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	750000	USD
CY2016	arth	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	3114654	USD
CY2015	arth	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	3015966	USD
CY2016	arth	Issuance Of Inducement Of Shares IssuanceOfInducementOfShares	0	USD
CY2015	arth	Issuance Of Inducement Of Shares IssuanceOfInducementOfShares	135352	USD
CY2016	arth	Reclassificationofseriesaandcwarrantsfromderivativeliabilitiestoequity Reclassificationofseriesaandcwarrantsfromderivativeliabilitiestoequity	0	USD
CY2015	arth	Reclassificationofseriesaandcwarrantsfromderivativeliabilitiestoequity Reclassificationofseriesaandcwarrantsfromderivativeliabilitiestoequity	3263753	USD
CY2016	arth	Financing Costs On Issuance Of Common Stock And Warrants FinancingCostsOnIssuanceOfCommonStockAndWarrants	5715	USD
CY2015	arth	Financing Costs On Issuance Of Common Stock And Warrants FinancingCostsOnIssuanceOfCommonStockAndWarrants	0	USD
CY2014Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	224000	USD
CY2015Q1	arth	Gain Loss On Warrant Derivative Modification GainLossOnWarrantDerivativeModification	624016	USD
CY2015Q2	us-gaap	Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity	3263753	USD
CY2015Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	605000	USD
CY2016Q3	us-gaap	Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral	354988	USD
CY2016	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	395012	USD
CY2013Q2	arth	Increase In Aggregate Number Of Shares IncreaseInAggregateNumberOfShares	3000000	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7657	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.1944	pure
CY2016	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm	P0Y
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0059	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10776500	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3160000	shares
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	362500	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1194790	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12379210	shares
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	9033226	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	12379210	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.3
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.43
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.32
CY2016	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedWeightedAverageRemainingContractualTerm	P0Y
CY2016	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm	P0Y
CY2015	arth	License Maintenance Costs LicenseMaintenanceCosts	45000	USD
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y4M24D
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
CY2016	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodAggregateIntrinsicValue	3304049	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	4341816	USD
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.39
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.33
CY2016	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice	0.31
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	0.33
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P0Y
CY2016Q3	us-gaap	Interest Payable Current InterestPayableCurrent	304770	USD
CY2015Q3	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2016Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	136657075	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	136657075	shares
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	107592205	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	107592205	shares
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	-6892443	USD
CY2015	arth	Stock Issued During Period Value Restricted Stock For Services StockIssuedDuringPeriodValueRestrictedStockForServices	166157	USD
CY2016	arth	Stock Issued During Period Value Restricted Stock For Services StockIssuedDuringPeriodValueRestrictedStockForServices	52500	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	USD
CY2016	arth	Stock Issued During Period Value Warrant Exercised StockIssuedDuringPeriodValueWarrantExercised	0	USD
CY2015	arth	Stock Issued During Period Value Private Placement Funding StockIssuedDuringPeriodValuePrivatePlacementFunding	3015966	USD
CY2016	arth	Stock Issued During Period Value Private Placement Funding StockIssuedDuringPeriodValuePrivatePlacementFunding	3108939	USD
CY2015	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	151173	USD
CY2016	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	644900	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1047685	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1098160	USD
CY2016	arth	Convertible Note Embedded Of Convertible Beneficial Conversion Feature ConvertibleNoteEmbeddedOfConvertibleBeneficialConversionFeature	0	USD
CY2015	arth	Convertible Note Embedded Of Convertible Beneficial Conversion Feature ConvertibleNoteEmbeddedOfConvertibleBeneficialConversionFeature	354988	USD
CY2016	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u>Use of Estimates</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u>Concentration of Credit Risk</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q3	arth	Deferred Tax Assets Capitalized Expenditures DeferredTaxAssetsCapitalizedExpenditures	802769	USD
CY2015Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	164252	USD
CY2016Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1463474	USD
CY2016Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3925	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	USD
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	USD
CY2016Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5424530	USD
CY2015Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3748426	USD
CY2016Q3	arth	Deferred Tax Assets Capitalized Expenditures DeferredTaxAssetsCapitalizedExpenditures	1104928	USD
CY2016Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	1578	USD
CY2015Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	1569	USD
CY2016Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	171083	USD
CY2015Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	124716	USD
CY2015Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5856386	USD
CY2015Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5856386	USD
CY2015Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2016Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	13675000	USD
CY2016Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	12814000	USD
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2767000	USD
CY2016Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	0	USD
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0240	pure
CY2016	arth	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate	0.00	pure
CY2016Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	977882	USD
CY2015Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	966824	USD
CY2016	us-gaap	Interest Expense Debt InterestExpenseDebt	11000	USD
CY2015	us-gaap	Interest Expense Debt InterestExpenseDebt	11000	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2447527	shares
CY2016	arth	License Maintenance Costs LicenseMaintenanceCosts	50000	USD
CY2016Q3	us-gaap	Notes Payable Current NotesPayableCurrent	899627	USD
CY2015Q3	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2016Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	78255	USD
CY2015Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	966824	USD
CY2015	arth	Stock Issued During Period Value Warants Exercised StockIssuedDuringPeriodValueWarantsExercised	3600000	USD
CY2016	arth	Stock Issued During Period Value Warants Exercised StockIssuedDuringPeriodValueWarantsExercised	2708749	USD
CY2015	arth	Stock Issued During Period Value Extending Warrants And Eliminating Ratchet Provision StockIssuedDuringPeriodValueExtendingWarrantsAndEliminatingRatchetProvision	135352	USD
CY2015	arth	Reclassification Of Warrants ReclassificationOfWarrants	3263753	USD
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4341816	USD
CY2016	arth	Warrant Exercised In Cashless Basis WarrantExercisedInCashlessBasis	2334	USD
CY2015	arth	Warrant Exercised In Cashless Basis WarrantExercisedInCashlessBasis	686	USD
CY2016	arth	Stock Option Exercised In Cashless Basis StockOptionExercisedInCashlessBasis	69	USD
CY2015	arth	Stock Option Exercised In Cashless Basis StockOptionExercisedInCashlessBasis	462	USD
CY2015Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.20
CY2015	arth	Gain Loss On Warrant Derivative Modification GainLossOnWarrantDerivativeModification	2980829	USD
CY2015	us-gaap	Other Noncash Expense OtherNoncashExpense	896763	USD

Files In Submission

Name	View Source	Status
0001144204-16-137852-index-headers.html	Edgar Link	pending
0001144204-16-137852-index.html	Edgar Link	pending
0001144204-16-137852.txt	Edgar Link	pending
0001144204-16-137852-xbrl.zip	Edgar Link	pending
arth-20160930.xml	Edgar Link	completed
arth-20160930.xsd	Edgar Link	pending
arth-20160930_cal.xml	Edgar Link	unprocessable
arth-20160930_def.xml	Edgar Link	unprocessable
arth-20160930_lab.xml	Edgar Link	unprocessable
arth-20160930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v453828_10k.htm	Edgar Link	pending
v453828_ex23-1.htm	Edgar Link	pending
v453828_ex31-1.htm	Edgar Link	pending
v453828_ex31-2.htm	Edgar Link	pending
v453828_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARTH
Arch Therapeutics, Inc. Stock $arth

2016 Q3 Form 10-K Financial Statement

#000114420416137852 Filed on December 05, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARTH Arch Therapeutics, Inc. Stock $arth

2016 Q3 Form 10-K Financial Statement

#000114420416137852 Filed on December 05, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARTH
Arch Therapeutics, Inc. Stock $arth